J Ethnopharmacol:抑肝散对抽动秽语综合征儿童青少年精神行为的影响,一项随机、双盲、对照的初步研究

2022-04-12 紫菀款冬 MedSci原创

进行一项随机、双盲、对照的初步研究,探讨抑肝散是否可以缓解儿童和青少年的抽动秽语综合征症状。

背景:小儿抽动秽语综合征(GTS),也称Tourette综合征(TS),是一类以进行性发展的、不自主的、突发的、无节律的多部位、形式多样的运动抽动,同时伴有一种或多种爆发性发声和秽语为主要表现的抽动障碍。

抑肝散(YGS)源于明代薛铠的《保婴撮要》,由软柴胡、甘草、川芎、当归、白术(炒)、茯苓、钩藤组成,可抑肝健脾,清热解痉;用治肝经虚热发搐,或痰热咬牙,或惊悸寒热,或木乘土而呕吐痰饮,腹胀少食,睡卧不安。研究表明,YGS可用于治疗儿童躁动不安;治疗痴呆行为心理症状的疗效与利培酮、氟伏沙明相似,可能通过抑制多巴胺功能发挥作用。YGS可以在大脑的许多部位发挥作用,包括额叶皮质和海马体,并可以缓解痴呆患者的攻击性、躁动和幻觉。

目的:进行一项随机、双盲、对照的初步研究,探讨YGS是否可以缓解儿童和青少年的TS症状。

方法:根据《精神疾病诊断统计手册》第五版的诊断标准,TS由儿科神经病学或儿科精神病学专家诊断,耶鲁综合抽动严重程度量表(YGTSS)评分≥20分的患者被纳入研究。将38例TS患者分为对照组(CG组,19例,口服YGS安慰剂——90%淀粉+ 10% YGS,2.5 g,每日3次)和治疗组(TG组,19例,接受YGS治疗4周)。在试验期间,患者仅接受YGS或YGS安慰剂治疗,不允许服用任何西药或其他中草药。

主要观察指标是YGTSS评分的变化;次要指标是抽动秽语综合征临床综合印象量表(CGI-TS)评分的变化

第一次评估是在口服YGS或YGS安慰剂(V1)之前进行;在开始口服YGS或YGS安慰剂后,第2次(V2,7±1天)、第3次(V3,14±1天)、第4次(V4,21±1天)和第5次(V5,28±1天)进行评估。

此外,在V1和V5时检测外周血谷草转氨酶(GOT)谷丙转氨酶(GPT)血尿素氮(BUN)肌酐K+免疫球蛋白E (IgE)水平的变化。

结果:CG组和TG组在口服YGS前和口服2周、3周、4周后发声抽动总评分差异无统计学意义;但是口服YGS 1周后,TG组的发声抽动总评分为1.89±1.10,低于CG组的3.06±1.39(P =0.008)。

比较两组在各个时间点的CGI-TS严重程度发现,在V5时,TG组的严重程度(得分≧4)低于CG组(TG和CG分别为16.7%和47.1%),然而这种差异并不显著(P = 0.053)。此外,V1、V5两个检测节点外周血中GOT、GPT、BUN、肌酐、K+、IgE水平在组间差异无统计学意义。

结论:口服一周YGS只能降低发声抽动的强度,表明YGS可以在短期内改善发声抽动的强度;此外Tourette综合征的儿童和青少年口服4周YGS的依从性也较高。不足的是,此次只是初步研究,选择合适的安慰剂和剂量以及长期观察是未来研究的关键领域。

 

文献来源:

Huang, C. H., Liao, W. L., Lee, D. Y., et al. (2022). Effects of Yi-Gan-san on the psychiatric behavior of children and adolescents with Tourette's Syndrome: A randomized, double-blind, controlled preliminary study. Journal of ethnopharmacology, 290, 115098. https://doi.org/10.1016/j.jep.2022.115098

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787784, encodeId=f5ae1e87784b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 18 20:54:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788466, encodeId=a1141e8846609, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 06:54:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996461, encodeId=154f1996461ac, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 02 11:54:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908692, encodeId=153b190869279, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Aug 30 11:54:07 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775636, encodeId=024d1e7563607, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Feb 11 09:54:07 CST 2023, time=2023-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708243, encodeId=527c1e0824334, content=<a href='/topic/show?id=f437285150b' target=_blank style='color:#2F92EE;'>#儿童青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28515, encryptionId=f437285150b, topicName=儿童青少年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95d31554106, createdName=1249894fm83暂无昵称, createdTime=Wed May 11 05:54:07 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210967, encodeId=f87c121096e40, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:36 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210966, encodeId=f26f121096639, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:31 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432302, encodeId=15b41432302fd, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573131, encodeId=3dfa15e3131a2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
    2022-08-18 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787784, encodeId=f5ae1e87784b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 18 20:54:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788466, encodeId=a1141e8846609, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 06:54:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996461, encodeId=154f1996461ac, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 02 11:54:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908692, encodeId=153b190869279, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Aug 30 11:54:07 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775636, encodeId=024d1e7563607, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Feb 11 09:54:07 CST 2023, time=2023-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708243, encodeId=527c1e0824334, content=<a href='/topic/show?id=f437285150b' target=_blank style='color:#2F92EE;'>#儿童青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28515, encryptionId=f437285150b, topicName=儿童青少年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95d31554106, createdName=1249894fm83暂无昵称, createdTime=Wed May 11 05:54:07 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210967, encodeId=f87c121096e40, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:36 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210966, encodeId=f26f121096639, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:31 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432302, encodeId=15b41432302fd, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573131, encodeId=3dfa15e3131a2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787784, encodeId=f5ae1e87784b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 18 20:54:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788466, encodeId=a1141e8846609, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 06:54:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996461, encodeId=154f1996461ac, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 02 11:54:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908692, encodeId=153b190869279, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Aug 30 11:54:07 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775636, encodeId=024d1e7563607, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Feb 11 09:54:07 CST 2023, time=2023-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708243, encodeId=527c1e0824334, content=<a href='/topic/show?id=f437285150b' target=_blank style='color:#2F92EE;'>#儿童青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28515, encryptionId=f437285150b, topicName=儿童青少年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95d31554106, createdName=1249894fm83暂无昵称, createdTime=Wed May 11 05:54:07 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210967, encodeId=f87c121096e40, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:36 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210966, encodeId=f26f121096639, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:31 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432302, encodeId=15b41432302fd, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573131, encodeId=3dfa15e3131a2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
    2022-05-02 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787784, encodeId=f5ae1e87784b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 18 20:54:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788466, encodeId=a1141e8846609, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 06:54:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996461, encodeId=154f1996461ac, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 02 11:54:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908692, encodeId=153b190869279, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Aug 30 11:54:07 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775636, encodeId=024d1e7563607, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Feb 11 09:54:07 CST 2023, time=2023-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708243, encodeId=527c1e0824334, content=<a href='/topic/show?id=f437285150b' target=_blank style='color:#2F92EE;'>#儿童青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28515, encryptionId=f437285150b, topicName=儿童青少年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95d31554106, createdName=1249894fm83暂无昵称, createdTime=Wed May 11 05:54:07 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210967, encodeId=f87c121096e40, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:36 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210966, encodeId=f26f121096639, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:31 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432302, encodeId=15b41432302fd, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573131, encodeId=3dfa15e3131a2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787784, encodeId=f5ae1e87784b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 18 20:54:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788466, encodeId=a1141e8846609, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 06:54:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996461, encodeId=154f1996461ac, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 02 11:54:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908692, encodeId=153b190869279, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Aug 30 11:54:07 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775636, encodeId=024d1e7563607, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Feb 11 09:54:07 CST 2023, time=2023-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708243, encodeId=527c1e0824334, content=<a href='/topic/show?id=f437285150b' target=_blank style='color:#2F92EE;'>#儿童青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28515, encryptionId=f437285150b, topicName=儿童青少年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95d31554106, createdName=1249894fm83暂无昵称, createdTime=Wed May 11 05:54:07 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210967, encodeId=f87c121096e40, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:36 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210966, encodeId=f26f121096639, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:31 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432302, encodeId=15b41432302fd, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573131, encodeId=3dfa15e3131a2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
    2023-02-11 amyloid
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787784, encodeId=f5ae1e87784b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 18 20:54:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788466, encodeId=a1141e8846609, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 06:54:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996461, encodeId=154f1996461ac, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 02 11:54:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908692, encodeId=153b190869279, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Aug 30 11:54:07 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775636, encodeId=024d1e7563607, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Feb 11 09:54:07 CST 2023, time=2023-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708243, encodeId=527c1e0824334, content=<a href='/topic/show?id=f437285150b' target=_blank style='color:#2F92EE;'>#儿童青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28515, encryptionId=f437285150b, topicName=儿童青少年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95d31554106, createdName=1249894fm83暂无昵称, createdTime=Wed May 11 05:54:07 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210967, encodeId=f87c121096e40, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:36 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210966, encodeId=f26f121096639, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:31 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432302, encodeId=15b41432302fd, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573131, encodeId=3dfa15e3131a2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1787784, encodeId=f5ae1e87784b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 18 20:54:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788466, encodeId=a1141e8846609, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 06:54:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996461, encodeId=154f1996461ac, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 02 11:54:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908692, encodeId=153b190869279, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Aug 30 11:54:07 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775636, encodeId=024d1e7563607, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Feb 11 09:54:07 CST 2023, time=2023-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708243, encodeId=527c1e0824334, content=<a href='/topic/show?id=f437285150b' target=_blank style='color:#2F92EE;'>#儿童青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28515, encryptionId=f437285150b, topicName=儿童青少年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95d31554106, createdName=1249894fm83暂无昵称, createdTime=Wed May 11 05:54:07 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210967, encodeId=f87c121096e40, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:36 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210966, encodeId=f26f121096639, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:31 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432302, encodeId=15b41432302fd, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573131, encodeId=3dfa15e3131a2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
    2022-04-13 ms2000001980585227

    有用

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1787784, encodeId=f5ae1e87784b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 18 20:54:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788466, encodeId=a1141e8846609, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 06:54:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996461, encodeId=154f1996461ac, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 02 11:54:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908692, encodeId=153b190869279, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Aug 30 11:54:07 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775636, encodeId=024d1e7563607, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Feb 11 09:54:07 CST 2023, time=2023-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708243, encodeId=527c1e0824334, content=<a href='/topic/show?id=f437285150b' target=_blank style='color:#2F92EE;'>#儿童青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28515, encryptionId=f437285150b, topicName=儿童青少年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95d31554106, createdName=1249894fm83暂无昵称, createdTime=Wed May 11 05:54:07 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210967, encodeId=f87c121096e40, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:36 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210966, encodeId=f26f121096639, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:31 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432302, encodeId=15b41432302fd, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573131, encodeId=3dfa15e3131a2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
    2022-04-13 ms2000001980585227

    学习了。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1787784, encodeId=f5ae1e87784b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 18 20:54:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788466, encodeId=a1141e8846609, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 06:54:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996461, encodeId=154f1996461ac, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 02 11:54:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908692, encodeId=153b190869279, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Aug 30 11:54:07 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775636, encodeId=024d1e7563607, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Feb 11 09:54:07 CST 2023, time=2023-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708243, encodeId=527c1e0824334, content=<a href='/topic/show?id=f437285150b' target=_blank style='color:#2F92EE;'>#儿童青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28515, encryptionId=f437285150b, topicName=儿童青少年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95d31554106, createdName=1249894fm83暂无昵称, createdTime=Wed May 11 05:54:07 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210967, encodeId=f87c121096e40, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:36 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210966, encodeId=f26f121096639, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:31 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432302, encodeId=15b41432302fd, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573131, encodeId=3dfa15e3131a2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1787784, encodeId=f5ae1e87784b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 18 20:54:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788466, encodeId=a1141e8846609, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Sep 26 06:54:07 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996461, encodeId=154f1996461ac, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon May 02 11:54:07 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908692, encodeId=153b190869279, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Aug 30 11:54:07 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775636, encodeId=024d1e7563607, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Feb 11 09:54:07 CST 2023, time=2023-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708243, encodeId=527c1e0824334, content=<a href='/topic/show?id=f437285150b' target=_blank style='color:#2F92EE;'>#儿童青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28515, encryptionId=f437285150b, topicName=儿童青少年)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95d31554106, createdName=1249894fm83暂无昵称, createdTime=Wed May 11 05:54:07 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210967, encodeId=f87c121096e40, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:36 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210966, encodeId=f26f121096639, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d0b8106534, createdName=ms2000001980585227, createdTime=Wed Apr 13 21:09:31 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432302, encodeId=15b41432302fd, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573131, encodeId=3dfa15e3131a2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Wed Apr 13 11:54:07 CST 2022, time=2022-04-13, status=1, ipAttribution=)]
    2022-04-13 xlxchina

相关资讯

Medidata开放患者洞察计划,使申办者和合同研究组织能够在临床试验中利用其以患者为中心的专有设计流程

Medidata将开放其“患者洞察计划”,作为其新产品中的一项功能,旨在把以患者为中心的方法纳入临床试验方案和技术的设计与开发当中。

Science Advances:在体内植入“细胞药物工厂”,6天清除癌细胞,今年将开展临床试验

细胞因子(Cytokines)是一类可溶性分子信使,可响应抗原呈递细胞刺激,在体内激活和传递抗病免疫级联反应。在癌症免疫治疗中,外源性细胞因子可启动免疫系统激活以优化获得性抗肿瘤免疫反应。

JAAD:JAK抑制剂治疗特应性皮炎的临床试验中老年人的代表性不足

老年人约占特应性皮炎(AD)患者的13%。因此AD治疗的临床试验需要充分包括65岁以上的成年人,但老年人在许多疾病的临床试验中的代表性往往偏低,本文就这一情况进行了研究。

BiologyWorks k(now)TM新冠肺炎临床试验与RT-PCR检测的准确度一致率达99.1%

一项实质性临床试验发现,其手持式、可重复使用的新冠病毒分子检测设备的准确度与实验室RT-PCR检测准确度的一致率达99.1%。

阿南达医药科技与纽约大学格罗斯曼医学院宣布神经根性疼痛患者阿片类节量治疗临床试验入组首例患者

该试验将评估Nantheia™ A1002N5S用于神经根性疼痛综合征患者的阿片类节量治疗。

JNER:机器人辅助水平对接受辅助机器人康复的中风患者上肢功能的影响,一项随机临床试验的分析

上肢偏瘫(UE)是住院中风幸存者中最常见的情况之一,影响到三分之二的人群。UE的偏瘫会导致手臂和手的功能受损,从而对中风幸存者的日常活动产生负面影响。康复治疗是提高脑卒中患者运动技能和生存质量的基础。